Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.
Acute Disease
Anticoagulants
/ therapeutic use
Antithrombin III
/ metabolism
Biomarkers
/ blood
Blood Platelets
/ drug effects
COVID-19
/ blood
Critical Illness
Cytokine Release Syndrome
/ blood
Cytokines
/ blood
Disseminated Intravascular Coagulation
/ blood
Drug Resistance
Fibrin Fibrinogen Degradation Products
/ metabolism
Heparin
/ therapeutic use
Humans
SARS-CoV-2
/ pathogenicity
Survival Analysis
Venous Thromboembolism
/ blood
COVID-19 Drug Treatment
Antithrombin III
COVID-19
Coagulopathy
Heparin resistance
SARS-CoV critical illness
SARS-CoV2
Thrombosis
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
05
2020
revised:
12
06
2020
accepted:
30
06
2020
pubmed:
25
8
2020
medline:
20
2
2021
entrez:
25
8
2020
Statut:
ppublish
Résumé
As the current coronavirus pandemic continues and cases of COVID-19 critical illness rise, physicians and scientists across the globe are working to understand and study its pathophysiology. Part of the pathology of this illness may result from its prothrombotic potential as witnessed from derangements in coagulation and thrombotic complications reported in observational studies performed in China and Europe to findings of microthrombosis upon autopsy analysis of patients who succumbed to COVID-19. Multiple organizations, including the American Society of Hematology (ASH), recommend the routine use of prophylactic heparin to temper the thrombotic complications of this illness given its mortality benefit in severe COVID-19 infections. Reductions in circulating levels of Antithrombin III (AT), the primary mediator of heparin's action, is present in cases of coronavirus related critical illness. AT's use as a prognostic marker, an important effector of heparin resistance, and a potential therapeutic target for COVID-19 remains to be explored.
Identifiants
pubmed: 32829961
pii: S0268-960X(20)30081-3
doi: 10.1016/j.blre.2020.100731
pmc: PMC7832361
pii:
doi:
Substances chimiques
Anticoagulants
0
Biomarkers
0
Cytokines
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Antithrombin III
9000-94-6
Heparin
9005-49-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100731Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
J Thromb Haemost. 2020 Jun;18(6):1517-1519
pubmed: 32294295
PLoS One. 2020 Oct 29;15(10):e0241329
pubmed: 33119703
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Crit Care. 2006;10(2):R45
pubmed: 16542495
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Thromb Haemost. 2020 Jun;120(6):998-1000
pubmed: 32316063
Intensive Care Med. 1998 Jul;24(7):663-72
pubmed: 9722035
Shock. 2007 Aug;28(2):141-7
pubmed: 17515857
J Thromb Haemost. 2014 Sep;12(9):1470-9
pubmed: 24943516
J Thorac Cardiovasc Surg. 2002 Feb;123(2):213-7
pubmed: 11828278
Cochrane Database Syst Rev. 2016 Feb 08;2:CD005370
pubmed: 26858174
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
J Med Virol. 2020 Sep;92(9):1449-1459
pubmed: 32242947
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124
pubmed: 32387623
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Ann Acad Med Singap. 2006 May;35(5):332-9
pubmed: 16830000
J Thromb Haemost. 2020 May;18(5):1020-1022
pubmed: 32239799
J Thromb Haemost. 2006 Jan;4(1):90-7
pubmed: 16409457
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Crit Care Clin. 2003 Jul;19(3):441-58
pubmed: 12848314
J Trauma Acute Care Surg. 2014 Apr;76(4):937-42; discussion 942-3
pubmed: 24662855
Thromb Haemost. 2016 Apr;115(4):712-28
pubmed: 26676884
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Chest. 1992 Mar;101(3):816-23
pubmed: 1531791
J Pathol. 2003 Jul;200(3):282-9
pubmed: 12845623
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
Intensive Care Med. 1998 Apr;24(4):336-42
pubmed: 9609411
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Intensive Care Med. 2020 Jun;46(6):1099-1102
pubmed: 32291463
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
J Clin Med. 2020 May 11;9(5):
pubmed: 32403217
Anesth Analg. 2013 Jun;116(6):1210-22
pubmed: 23408671
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Vox Sang. 2020 Aug;115(6):502-506
pubmed: 32347566
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Emerg Microbes Infect. 2020 Dec;9(1):687-690
pubmed: 32208840
Lung India. 2017 Jan-Feb;34(1):47-60
pubmed: 28144061
Clin Biochem Rev. 2004 May;25(2):121-32
pubmed: 18458712
Chest. 1993 May;103(5):1536-42
pubmed: 8486040
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Jun;15(6):336-7
pubmed: 12837163
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Med Klin (Munich). 2009 Jun 15;104(6):441-9
pubmed: 19533051
Shock. 2003 Jul;20(1):5-9
pubmed: 12813361
Lancet. 2020 May 16;395(10236):e87-e88
pubmed: 32423587
JAMA. 2001 Oct 17;286(15):1869-78
pubmed: 11597289
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Semin Thromb Hemost. 1998;24(1):19-25
pubmed: 9515776
Open Access Emerg Med. 2017 Dec 28;10:25-29
pubmed: 29343993
N Engl J Med. 1999 Aug 19;341(8):586-92
pubmed: 10451465
Br J Haematol. 2001 Oct;115(1):3-12
pubmed: 11722403
Mediterr J Hematol Infect Dis. 2010 Aug 13;2(3):e2010024
pubmed: 21415977
Nat Rev Immunol. 2020 Jul;20(7):389-391
pubmed: 32439870
Lancet Respir Med. 2020 Jul;8(7):681-686
pubmed: 32473124
Front Immunol. 2019 Jan 31;10:55
pubmed: 30766533
J Orthop Surg (Hong Kong). 2017 Jan 1;25(1):170840616684501
pubmed: 28418276
J Thromb Thrombolysis. 2021 May;51(4):1107-1110
pubmed: 32246317
Scand J Haematol. 1979 May;22(5):442-8
pubmed: 472663
Ann Thorac Surg. 2000 Sep;70(3):873-7
pubmed: 11016326
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Int J Antimicrob Agents. 2020 May;55(5):105947
pubmed: 32201354
P T. 2013 Dec;38(12):764-79
pubmed: 24391399
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Thromb Haemost. 2020 Aug;18(8):1859-1865
pubmed: 32459046
Crit Care Med. 2020 Jun;48(6):e440-e469
pubmed: 32224769
Hematol Rep. 2015 Nov 23;7(4):5844
pubmed: 26733269
J Cardiovasc Pharmacol. 2013 Mar;61(3):204-14
pubmed: 23232839
Medicine (Baltimore). 2015 Oct;94(40):e1692
pubmed: 26448017
Clin Transl Sci. 2020 Nov;13(6):1087-1095
pubmed: 32881340
Thromb Haemost. 2009 May;101(5):806-12
pubmed: 19404531
Transfus Med Hemother. 2009;36(6):437-448
pubmed: 21245974
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Lancet. 2008 Feb 2;371(9610):387-94
pubmed: 18242412
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Indian J Anaesth. 2014 Sep;58(5):515-23
pubmed: 25535411
N Engl J Med. 2011 Apr 7;364(14):1305-14
pubmed: 21417952
Thromb Haemost. 2006 Jul;96(1):100-1
pubmed: 16807662
Clin Infect Dis. 2004 Feb 15;38(4):483-9
pubmed: 14765339
Blood. 2018 Feb 22;131(8):845-854
pubmed: 29255070
Lancet Haematol. 2020 May;7(5):e362-e363
pubmed: 32278361
Acad Emerg Med. 2010 Jun;17(6):589-97
pubmed: 20624138